미국의 지속적 기도 양압기(CPAP) 시장 규모, 판매 대수, 평균 판매 가격 동향, 점유율 및 예측 분석 보고서 : 접속성별, 최종 용도별, 부문별 예측(2026-2033년)

U.S. Continuous Positive Airway Pressure Devices Market Summary

The U.S. continuous positive airway pressure devices market size was estimated at USD 1.35 billion in 2025 and is projected to reach USD 2.07 billion by 2033, growing at a CAGR of 5.50% from 2026 to 2033. This is attributed to the rising prevalence of sleep apnea and respiratory disorders, technological advancements in continuous positive airway pressure devices (CPAP) devices, growing awareness and diagnosis of sleep apnea, and favorable reimbursement policies.

For instance, Medicare covers a 3-month trial of CPAP devices and accessories for individuals diagnosed with obstructive sleep apnea. The incidence of sleep apnea and other respiratory disorders is on the rise in the U.S., primarily due to factors such as obesity, sedentary lifestyles, and an aging population. According to the Centers for Disease Control and Prevention (CDC) estimates published in May 2024, between August 2021 and August 2023, the obesity rate among adults was 40.3%, with no notable differences between women & men. Obesity was higher in adults aged 41-60 compared to those aged 20-39 and those 60 and older. This growing obesity rate contributes significantly to the increasing prevalence of sleep apnea, thereby driving the demand for CPAP devices.

Moreover, continuous innovations in CPAP technology have significantly enhanced patient comfort and therapy effectiveness. Modern CPAP machines feature quieter motors, compact designs, integrated humidification systems, and advanced data-tracking capabilities. These improvements address common patient concerns, such as noise and discomfort, thereby increasing therapy adherence rates.

Government health agencies and non-profit organizations frequently conduct public awareness initiatives to inform individuals about sleep apnea and treatment needs. For instance, in May 2024, the CDC in the U.S. incorporated sleep apnea into its broader public health campaigns on sleep hygiene and the management of chronic diseases.

The rental model plays a significant role in shaping the adoption of continuous positive airway pressure devices in the U.S., as well as pricing and revenue dynamics. CPAP devices are commonly provided to patients on a rent-to-own basis, typically over a 10 to 13-month period, driven largely by insurance reimbursement policies, including those of Medicare and private payers. In addition, this model reduces upfront costs for patients, enhances therapy initiation rates, and enables payers to verify compliance before full ownership, thereby facilitating broader market penetration.

However, it also slows immediate device sales revenue recognition for manufacturers, shifts purchasing power toward DME providers, and increases the importance of long-term patient adherence, remote monitoring, and replacement cycles (such as masks, tubing, and filters). CPAP rentals contribute to steady, recurring demand, greater price sensitivity, and stronger emphasis on connected devices and service-based differentiation in the U.S. continuous positive airway pressure (CPAP) devices industry.

U.S. Continuous Positive Airway Pressure Devices Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2026 to 2033. For this study, Grand View Research has segmented the U.S. continuous positive airway pressure devices market report based on connectivity and end use.

• Connectivity Outlook (Volume, 000' Units; Revenue, USD Million, 2021 - 2033)
• Connected
  • Bluetooth-Connected CPAP
  • Wi-Fi & Cellular Connected CPAP
  • Hybrid-Connected
• Non-Connected
• End Use Outlook (Volume, 000' Units; Revenue, USD Million, 2021 - 2033)
• Home Care Settings
• Hospitals & Clinics
• Others (Long-Term Care Facilities, etc.)

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Segment Definitions
• 1.2. Estimates and Forecast Timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
  • 1.4.5. Details of Primary Research
  • 1.4.6. Research Assumption
• 1.5. Information or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Data Visualization
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
• 1.8. Objectives
  • 1.8.1. Objective - 1
  • 1.8.2. Objective - 2
  • 1.8.3. Objective - 3
• 1.9. List of Secondary Sources
• 1.10. List of Secondary Sources

Chapter 2. Executive Summary

• 2.1. U.S. CPAP Devices Market
  • 2.1.1. Market Snapshot
  • 2.1.2. Segment Snapshot
    • 2.1.2.1. Connectivity segment outlook
    • 2.1.2.2. End Use segment outlook
  • 2.1.3. Competitive Landscape Snapshot

Chapter 3. Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Trends and Outlook
• 3.3. Market Dynamics
  • 3.3.1. Market Driver Analysis
    • 3.3.1.1. Rising incidence of obstructive sleep apnea (OSA)
    • 3.3.1.2. Technological advancements
    • 3.3.1.3. Supportive initiatives by government and private organizations for CPAP devices
  • 3.3.2. Market Restraint Analysis
    • 3.3.2.1. Product recalls & failure
    • 3.3.2.2. Complex regulatory framework pertaining to CPAP devices
  • 3.3.3. Market Opportunity Analysis
    • 3.3.3.1. Growing adoption of CPAP devices in home care settings
  • 3.3.4. Market Challenges Analysis
    • 3.3.4.1. Regulatory and reimbursement challenges
• 3.4. U.S. CPAP Devices Market Analysis Tools: PESTEL
  • 3.4.1. Political & Legal
  • 3.4.2. Economic & Social
  • 3.4.3. Technology
  • 3.4.4. Environment
• 3.5. U.S. CPAP Market Analysis Tools: Porter's

Chapter 4. U.S. CPAP Devices Market: Connectivity Estimates & Trend Analysis

• 4.1. U.S. CPAP Devices Market: Connectivity Movement Analysis
• 4.2. U.S. CPAP Devices Market: Connectivity Segment Dashboard
• 4.3. Connectivity Movement & Market Share Analysis, 2025 & 2033
• 4.4. U.S. Connectivity Market Estimates & Forecast, by Connectivity
• 4.5. Connected
  • 4.5.1. Market Estimates & Forecast, 2021 - 2033 (USD Million) (000' Units)
  • 4.5.2. Bluetooth-Connected CPAP
    • 4.5.2.1. Market Estimates & Forecast, 2021 - 2033 (USD Million) (000' Units)
  • 4.5.3. Wi-Fi & Cellular Connected CPAP
    • 4.5.3.1. Market Estimates & Forecast, 2021 - 2033 (USD Million) (000' Units)
  • 4.5.4. Hybrid-Connected
    • 4.5.4.1. Market Estimates & Forecast, 2021 - 2033 (USD Million) (000' Units)
• 4.6. Non-Connected
  • 4.6.1. Market Estimates & Forecast, 2021 - 2033 (USD Million) (000' Units)

Chapter 5. U.S. CPAP Devices Market: End Use Estimates & Trend Analysis

• 5.1. U.S. CPAP Devices Market: End Use Movement Analysis
• 5.2. U.S. CPAP Devices Market: End Use Segment Dashboard
• 5.3. End Use Movement & Market Share Analysis, 2025 & 2033
• 5.4. U.S. CPAP Devices Market Estimates & Forecast, by End Use
• 5.5. Home Care Settings
  • 5.5.1. Market Estimates & Forecast, 2021 - 2033 (USD Million) (000' Units)
• 5.6. Hospitals & Clinics
  • 5.6.1. Market Estimates & Forecast, 2021 - 2033 (USD Million) (000' Units)
• 5.7. Others (Long-Term Care Facilities, etc.)
  • 5.7.1. Market Estimates & Forecast, 2021 - 2033 (USD Million) (000' Units)

Chapter 6. Competitive Landscape

• 6.1. Company Categorization
• 6.2. Strategies of Market Players for Entry and Exit and Their Impact on Market Competitors
• 6.3. Company Market Position Analysis
• 6.4. Company Share Analysis, from 2012 to 2025 (%)
• 6.5. Company Profiles/Listing
  • 6.5.1. ResMed
    • 6.5.1.1. Overview
    • 6.5.1.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2025)
    • 6.5.1.3. Product benchmarking
    • 6.5.1.4. Strategic initiatives
  • 6.5.2. Koninklijke Philips N.V.
    • 6.5.2.1. Overview
    • 6.5.2.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2025)
    • 6.5.2.3. Product benchmarking
    • 6.5.2.4. Strategic initiatives
  • 6.5.3. Fisher & Paykel Healthcare Limited
    • 6.5.3.1. Overview
    • 6.5.3.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2025)
    • 6.5.3.3. Product benchmarking
    • 6.5.3.4. Strategic initiatives
  • 6.5.4. React Health (3B Medical)
    • 6.5.4.1. Overview
    • 6.5.4.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2025)
    • 6.5.4.3. Product benchmarking
    • 6.5.4.4. Strategic initiatives
  • 6.5.5. Lowenstein Medical
    • 6.5.5.1. Overview
    • 6.5.5.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2025)
    • 6.5.5.3. Product benchmarking
    • 6.5.5.4. Strategic initiatives
  • 6.5.6. BMC Medical
    • 6.5.6.1. Overview
    • 6.5.6.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2025)
    • 6.5.6.3. Product benchmarking
    • 6.5.6.4. Strategic initiatives
  • 6.5.7. Wellell (Apex Medical)
    • 6.5.7.1. Overview
    • 6.5.7.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2025)
    • 6.5.7.3. Product benchmarking
    • 6.5.7.4. Strategic initiatives
  • 6.5.8. Armstrong Medical
    • 6.5.8.1. Overview
    • 6.5.8.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2025)
    • 6.5.8.3. Product benchmarking
    • 6.5.8.4. Strategic initiatives
  • 6.5.9. Breas Medical
    • 6.5.9.1. Overview
    • 6.5.9.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2025)
    • 6.5.9.3. Product benchmarking
    • 6.5.9.4. Strategic initiatives
  • 6.5.10. SEFAM
    • 6.5.10.1. Overview
    • 6.5.10.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2025)
    • 6.5.10.3. Product benchmarking
    • 6.5.10.4. Strategic initiatives
  • 6.5.11. Transcend Inc. (Somnetics International, Inc.)
    • 6.5.11.1. Overview
    • 6.5.11.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2025)
    • 6.5.11.3. Product benchmarking
    • 6.5.11.4. Strategic initiatives
  • 6.5.12. Trudell Medical (Vyaire)
    • 6.5.12.1. Overview
    • 6.5.12.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2025)
    • 6.5.12.3. Product benchmarking
    • 6.5.12.4. Strategic initiatives
  • 6.5.13. Medical Depot, Inc. dba Drive DeVilbiss Healthcare
    • 6.5.13.1. Overview
    • 6.5.13.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2025)
    • 6.5.13.3. Product benchmarking
    • 6.5.13.4. Strategic initiatives
  • 6.5.14. Invacare Corporation
    • 6.5.14.1. Overview
    • 6.5.14.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2025)
    • 6.5.14.3. Product benchmarking
    • 6.5.14.4. Strategic initiatives
  • 6.5.15. Apria Healthcare Group LLC
    • 6.5.15.1. Overview
    • 6.5.15.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2025)
    • 6.5.15.3. Product benchmarking
    • 6.5.15.4. Strategic initiatives
  • 6.5.16. Rotech Healthcare Inc.
    • 6.5.16.1. Overview
    • 6.5.16.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2025)
    • 6.5.16.3. Product benchmarking
    • 6.5.16.4. Strategic initiatives
  • 6.5.17. Others
    • 6.5.17.1. Overview
    • 6.5.17.2. Company performance (Unit Volume, ASP Trend & Market Value from 2012 to 2025)
    • 6.5.17.3. Product benchmarking
    • 6.5.17.4. Strategic initiatives
• 6.6. U.S CPAP Devices: Sales Model Composition (Rental vs. Direct Purchase), 2020 - 2024
• 6.7. U.S. PAP Device DME Distributor-Level Profiles
  • 6.7.1. Lincare Holdings Inc.
    • 6.7.1.1. Estimated CPAP-related revenue and units (2020 - 2024E)
    • 6.7.1.2. % contribution of each manufacturer within that DME
    • 6.7.1.3. Sales model mix (% rental vs. direct)
    • 6.7.1.4. Key partnerships and manufacturer
    • 6.7.1.5. Notable strategic changes post-Philips recall
  • 6.7.2. Rotech Healthcare Inc.
    • 6.7.2.1. Estimated CPAP-related revenue and units (2020 - 2024E)
    • 6.7.2.2. % contribution of each manufacturer within that DME
    • 6.7.2.3. Sales model mix (% rental vs. direct)
    • 6.7.2.4. Key partnerships and manufacturer
    • 6.7.2.5. Notable strategic changes post-Philips recall
  • 6.7.3. AdaptHealth
    • 6.7.3.1. Estimated CPAP-related revenue and units (2020 - 2024E)
    • 6.7.3.2. % contribution of each manufacturer within that DME
    • 6.7.3.3. Sales model mix (% rental vs. direct)
    • 6.7.3.4. Key partnerships and manufacturer
    • 6.7.3.5. Notable strategic changes post-Philips recall
  • 6.7.4. Aeroflow Health
    • 6.7.4.1. Estimated CPAP-related revenue and units (2020 - 2024E)
    • 6.7.4.2. % contribution of each manufacturer within that DME
    • 6.7.4.3. Sales model mix (% rental vs. direct)
    • 6.7.4.4. Key partnerships and manufacturer
    • 6.7.4.5. Notable strategic changes post-Philips recall
  • 6.7.5. CPAP.com
    • 6.7.5.1. Estimated CPAP-related revenue and units (2020 - 2024E)
    • 6.7.5.2. % contribution of each manufacturer within that DME
    • 6.7.5.3. Sales model mix (% rental vs. direct)
    • 6.7.5.4. Key partnerships and manufacturer
    • 6.7.5.5. Notable strategic changes post-Philips recall
  • 6.7.6. AHOM
    • 6.7.6.1. Estimated CPAP-related revenue and units (2020 - 2024E)
    • 6.7.6.2. % contribution of each manufacturer within that DME
    • 6.7.6.3. Sales model mix (% rental vs. direct)
    • 6.7.6.4. Key partnerships and manufacturer
    • 6.7.6.5. Notable strategic changes post-Philips recall
  • 6.7.7. The CPAP Shop
    • 6.7.7.1. Estimated CPAP-related revenue and units (2020 - 2024E)
    • 6.7.7.2. % contribution of each manufacturer within that DME
    • 6.7.7.3. Sales model mix (% rental vs. direct)
    • 6.7.7.4. Key partnerships and manufacturer
    • 6.7.7.5. Notable strategic changes post-Philips recall
  • 6.7.8. Sleep Direct
    • 6.7.8.1. Estimated CPAP-related revenue and units (2020 - 2024E)
    • 6.7.8.2. % contribution of each manufacturer within that DME
    • 6.7.8.3. Sales model mix (% rental vs. direct)
    • 6.7.8.4. Key partnerships and manufacturer
    • 6.7.8.5. Notable strategic changes post-Philips recall
  • 6.7.9. Edgepark Medical Supplies
    • 6.7.9.1. Estimated CPAP-related revenue and units (2020 - 2024E)
    • 6.7.9.2. % contribution of each manufacturer within that DME
    • 6.7.9.3. Sales model mix (% rental vs. direct)
    • 6.7.9.4. Key partnerships and manufacturer
    • 6.7.9.5. Notable strategic changes post-Philips recall
  • 6.7.10. Apria Healthcare
    • 6.7.10.1. Estimated CPAP-related revenue and units (2020 - 2024E)
    • 6.7.10.2. % contribution of each manufacturer within that DME
    • 6.7.10.3. Sales model mix (% rental vs. direct)
    • 6.7.10.4. Key partnerships and manufacturer
    • 6.7.10.5. Notable strategic changes post-Philips recall